Harnessing hybrid molecules for drug development

Abstract

Harnessing hybrid molecules for drug development Stoyanka Nikolova, Professor from Paisii Hilendarski Plovdiv University, discusses the potential of harnessing hybrid molecules for drug development and their possible application in addressing the clinical challenge of irritable bowel syndrome. Irritable bowel syndrome (IBS) remains a clinical challenge. It’s the most common gastrointestinal disorder. IBS has no definitive treatment but could be controlled by non-pharmacologic management, eliminating some exacerbating factors such as certain drugs, stress conditions, and changes in dietary habits. Intestine peristaltic reflexes and sensory relays are significantly regulated by serotonin, predominantly found in intestine enterochromaffin cells.